Extract from:
http://uk.biz.yahoo.com/010801/183/c04qi.html
Wednesday August 1, 01:02 PM
...
Additionally, ILEX and its partners
are working to expand the market potential for Campath(R) by supporting
numerous clinical studies in other hematologic malignancies and transplant
regimens. The partnership intends to work out a development strategy for
Campath(R) in multiple sclerosis by year-end.
...
SAN ANTONIO--(BW HealthWire)